Question 1

A 32-year-old woman with bipolar I disorder is admitted during an acute manic episode. She has no comorbid conditions and uses an IUD for contraception. Her psychiatrist wants to achieve mood stabilization as quickly as possible. Which medication can be loaded to achieve therapeutic levels within 24-48 hours?

Accepted Answer

Lithium (answer A) has a narrow therapeutic window and cannot be safely loaded. Rapid lithium loading would cause toxicity (tremor, GI symptoms, renal risk, and at high levels, neurotoxicity). Lamotrigine (answer B) requires slow titration over weeks to avoid Stevens-Johnson syndrome and is not effective for acute mania (it is a maintenance agent for depression prevention). Carbamazepine (answer D) does not have a standard loading protocol for mania and rapid titration risks serious adverse effects including hyponatremia and Stevens-Johnson syndrome. Valproate loading at 20-30 mg/kg/day is a well-established inpatient strategy that achieves therapeutic levels (50-125 mcg/mL) within 24-48 hours, making it uniquely suited for acute mania requiring rapid stabilization. Note: her IUD provides reliable contraception, addressing the reproductive safety concern. If she were not using contraception, the risk-benefit conversation about valproate would be more complex.

Question 2

A patient with bipolar I disorder has been stable on valproate 1000mg daily (level 85 mcg/mL). Her psychiatrist adds lamotrigine for depression prevention. The lamotrigine is titrated using the standard monotherapy schedule (25mg daily for 2 weeks, then 50mg daily for 2 weeks, then increases to 200mg target). Three weeks into titration, she develops a diffuse rash with mucosal involvement consistent with the SJS/TEN spectrum. What error most likely contributed to this outcome?

Accepted Answer

This is the critical valproate-lamotrigine interaction question. Valproate inhibits UGT glucuronidation, which is lamotrigine's primary elimination pathway. This approximately doubles lamotrigine levels at any given dose. The standard monotherapy titration schedule produces levels that are safe when lamotrigine is prescribed alone, but that become dangerously high when valproate is co-prescribed. The modified titration schedule accounts for this by slowing the rate of increase and targeting a lower maintenance dose (typically 100mg when combined with valproate versus 200mg as monotherapy). Lamotrigine and valproate can be safely combined (answer A is wrong), and it is a common and effective combination for bipolar disorder. But the combination requires the prescriber to know and use the modified titration schedule. Valproate itself does not typically cause SJS-type rashes (answer C). Independent allergy to both (answer D) is not the likely explanation when a clear pharmacokinetic mechanism is present.

Question 3

A 68-year-old man with bipolar disorder and chronic kidney disease (albumin 2.1 g/dL) has been on valproate for years. His total valproate level returns at 72 mcg/mL, which appears therapeutic. However, he is increasingly sedated, confused, and has developed a new tremor over the past two weeks. What should you check?

Accepted Answer

This is the free versus total level concept. Valproate is approximately 90% protein-bound at therapeutic concentrations. This patient's albumin is 2.1 (significantly low), meaning far less protein is available to bind valproate. The result: a total level that looks normal (72 mcg/mL) but a free level that may be in the toxic range. His symptoms (sedation, confusion, tremor) are classic valproate toxicity. The clinical response: check a free valproate level, reduce the dose based on the free level, and monitor albumin. In any patient with hypoalbuminemia, renal impairment, or hepatic disease on valproate, free levels are more clinically meaningful than total levels. An EEG (answer A) might eventually be indicated but does not address the most likely explanation. A lithium level (answer C) is a reasonable screening step but does not explain the valproate-specific pharmacokinetic issue. A CT head (answer D) would be appropriate if there were focal neurological findings, but diffuse sedation, confusion, and tremor in a patient on valproate with low albumin point to medication toxicity first.

Valproate

Side Effects Worth Knowing

Sedation/Cognitive Slowing: common, dose-related

Weight Gain: clinically significant and often dose-dependent

GI Effects: nausea, vomiting, diarrhea, abdominal pain

Tremor: dose-dependent

Hair Loss/Thinning: distressing, underrecognized

Hepatotoxicity: boxed warning

Pancreatitis: boxed warning

Thrombocytopenia: dose-dependent

Hyperammonemia: can occur at any level

Teratogenicity: the defining reproductive safety concern

Menstrual Irregularity/Endocrine Effects: particularly in reproductive-age women

See This Medication in Action

References & Further Reading